The approval makes Dupixent the first FDA-approved therapy for allergic fungal rhinosinusitis, supported by Phase III data showing significant improvements in sinus opacification, nasal symptoms, and ...
The FDA has approved dupilumab to treat allergic fungal rhinosinusitis in adults and children ages 6 years and older.
The FDA approved dupilumab (Dupixent) for treating allergic fungal rhinosinusitis, a first for the condition, the agency announced on Wednesday. Approval stipulates use in individuals 6 years and ...
People with allergic fungal rhinosinusitis taking Dupixent saw significant improvement in congestion and sinus inflammation, ...
Dupixent (dupilumab) is now FDA-approved for adults and children aged 6 years and older with allergic fungal rhinosinusitis and prior sino-nasal surgery.
The FDA granted approval to dupilumab for treating patients aged 6 years and up with allergic fungal rhinosinusitis and a history of sino-nasal surgery, marking the first treatment approved for this ...
Approval in adults and children aged 6 years and older supported by Phase 3 trial demonstrating Dupixent significantly reduced nasal signs and ...
The NHS National Cancer Plan pledges to increase the amount of robotic surgery for cancer patients, up from 70,000 a year to ...
Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitisApproval in adults and children aged 6 years and older supported by phase 3 study ...
Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitisApproval in adults and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results